Page 9 - Zydus Lifesciences

Stocks to watch: Adani Transmission, HDFC AMC, ITC, Sun Pharma, Coal India

Stocks to watch on June 20, 2023: From HDFC AMC to Adani Transmission, here are few stocks to watch in Tuesday's trading session

Zydus Lifesciences gets USFDA nod for generic acne-treating drug

Zydus Lifesciences on Monday said it has received final approval from the US health regulator for its generic antibiotic Minocycline Hydrochloride extended-release tablets used for treatment of moderate to severe acne. The approval granted by the US Food and Drug Administration (USFDA) is for Minocycline Hydrochloride extended-release tablets of strengths 55 mg, 65 mg, and 115 mg, Zydus Lifesciences said in a regulatory filing. The tablet is used for treatment of moderate to severe acne in people aged 12 years and above. The product will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad, the company said.

Stocks to Watch today, June 14: Adani Group, Zee, RIL, Maruti, SBI Life

Stocks to watch on June 14, 2023: BHEL, Delta Corp, Indiabulls Housing Finance, IEX, India Cements and Manappuram Finance are the six stocks in F&O ban period today.

Zydus Lifesciences gets USFDA nod for anti-smoking and arthritis drugs

The stock for Zydus Lifesciences rose 1.52 percent on BSE to Rs 517.70 per share

Zydus Lifesciences gets USFDA nod to mfg generic version of Varenicline

Zydus Lifesciences on Tuesday said it has received final approval from the US health regulator to manufacture and market the generic version of Varenicline tablets indicated to treat smoking addiction. The approval by the US Food and Drug Administration (USFDA) is for Varenicline tablets of strengths 0.5 mg and 1 mg, Zydus said in a regulatory filing. The product will be launched shortly. It will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India, it added. Varenicline tablets, 0.5 mg and 1 mg had annual sales of USD 501 million in the US, the company said citing IQVIA MAT March 2023 data.

Zydus Lifesciences receives final USFDA approval for varenicline tablets

The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ

Zydus begins Phase-IV trial for non-alcoholic fatty liver disease drug

Saroglitazar Mg has been studied in two well-controlled Phase 3 clinical trials in patients with NAFLD and NASH in India

Zydus receives final approval from USFDA for esomeprazole magnesium

Esomeprazole magnesium for delayed-release oral suspension, 20 mg and 40 mg had annual sales of $42 mn in the United States

Stocks to Watch today, June 8: Banks, Auto, Lemon Tree, Adani Ent, Titagarh

Stocks to Watch on June 8, 2023: Shares of banks, automobile, and real estate companies could see considerable action in Thursday's session as the Reserve Bank of India (RBI) is slated to announce its

Zydus Lifesciences Q4 consolidated net profit dips 25.36% to Rs 296.6 cr

Zydus Lifesciences Ltd on Thursday reported a 25.36 per cent decline in consolidated net profit at Rs 296.6 crore in the fourth quarter ended March 31, 2023 impacted by impairment of goodwill of a wholly-owned subsidiary. The company, which had posted a consolidated net profit of Rs 397.4 crore in the same quarter of the previous fiscal, said its board has recommended a final dividend of Rs 6 per equity share of Re 1 each, subject to approval of shareholders at the Annual General Meeting scheduled to be held on August 11, 2023. Consolidated total revenue from operations stood at Rs 5,010.6 crore, as against Rs 3,805.6 crore in the corresponding period a year ago, Zydus Lifesciences said in a regulatory filing. Total expenses were higher at Rs 3,961.3 crore, as compared to Rs 3,311.8 crore in the year-ago quarter. During the quarter, Zydus Lifesciences said it incurred an exceptional item of Rs 594.1 crore as impairment of goodwill by Sentynl Therapeutics Inc, a wholly-owned subsidi

Zydus Lifesciences gets final approval from USFDA to manufacture ulcer drug

Sucralfate Tablets USP, 1 gram had annual sales of $84 million in the United States

ACC, Nykaa, HDFC AMC and Muthoot Fin likely to be dropped from Nifty 100

Jindal Steel and Power, Punjab National Bank, TVS Motor, Tube Investments and Zydus Lifesciences are expected to get added to the index

Zydus Lifesciences gets nod from USFDA for metronidazole topical cream

The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad

Escorts, Bank of India: Select midcap stocks are poised for up to 20% gains

Zydus Lifesciences, in particular, has been scaling 52-week highs with momentum staying highly elevated. Also, Aurobindo Pharma shares have seen a steeper rise, with aggressive chart structures.

Zydus Lifesciences gets USFDA nod to its generic medicine for high BP

Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture and market its generic version of metoprolol tartrate tablets used to treat high blood pressure. The approval granted by the United States Food and Drug Administration (USFDA) is for metoprolol tartrate tablets of strengths 25 mg, 50 mg, and 100 mg, Zydus Lifesciences said in a regulatory filing. The drug will be manufactured at the group's formulation manufacturing facility at Baddi in Himachal Pradesh, it added. Metoprolol is used with or without other medications to treat high blood pressure (hypertension), the company said, adding the medication is also used to treat chest pain (angina) and to improve survival after a heart attack. Metoprolol tartrate tablets 25 mg, 50 mg, and 100 mg had annual sales of USD 45.2 million in the US, the company said citing IQVIA MAT February 2023 data.

Stocks to Watch: SBI, ICICI Lombard, ONGC, Reliance, Oil India, Zydus Life

Stocks to Watch: ICICI Lombard General Insurance reported a 39.6 per cent surge in net profit in the January-March quarter (Q4) of FY23

Zydus Lifesciences gets USFDA nod for generic female hormone in US market

Zydus Lifesciences on Tuesday said it has received approval from the US regulator to market a generic female hormone, which helps reduce symptoms of menopause, in the US market. The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Estradiol Transdermal System USP in the American market. Estradiol transdermal system is indicated for prevention of postmenopausal osteoporosis. The company said the drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad in Gujarat. As per the IQVIA sales data, Estradiol Transdermal System had annual sales of USD 1.9 million in the US.

Booster dose: Zydus likely to arm India with single-dose malaria drug

In Phase-2 trials now, pill also works against drug-resistant malaria strains

Bulls ride on bank stocks to end higher for 7th session; Sensex up 311 pts

CLOSING BELL: The Nifty50 added 98 points to end at 17,722 level

Stocks to watch: JSW Steel, Cipla, Zydus Life, Kaveri Seed, Kalpataru Power

Stocks to watch today: From Cipla to Zydus Lifesciences, here are top stocks to watch in Tuesday's trading session